Cooperative Genomic Lesions in HRAS-Mutant Cancers Predict Resistance to Farnesyltransferase Inhibitors

The clinical development of farnesyltransferase inhibitors (FTI) for HRAS-mutant tumors showed mixed responses dependent on cancer type. Co-occurring mutations may affect response. We aimed to uncover cooperative genetic events specific to HRAS-mutant tumors and study their effect on FTI sensitivity...

Descripción completa

Detalles Bibliográficos
Autores principales: Nigam, Aradhya, Krishnamoorthy, Gnana, Chatila, Walid, Berman, Katherine, Saqcena, Mahesh, Walch, Henry, Ho, Alan, Schultz, Nikolaus, Fagin, James, Untch, Brian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Journal Experts 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10371077/
https://www.ncbi.nlm.nih.gov/pubmed/37503077
http://dx.doi.org/10.21203/rs.3.rs-3154719/v1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10371077/
https://www.ncbi.nlm.nih.gov/pubmed/37503077
http://dx.doi.org/10.21203/rs.3.rs-3154719/v1

Ejemplares similares